Parameters

Number

LRC

Univariate Analysis

(N= 85)

YES (N=29)

NO

(N=56)

Odd’s ratio (95% CI)

p-value

Age (years)

≤ 65

55 (64.70%)

20 (36.36%)

35 (63.63%)

Reference

> 65

30

(35.29%)

9

(30%)

21

(70%)

0.75 (0.288 to 1.948)

0.554

Sex

Male

53 (62.35%)

20 (37.73%)

33 (62.26%)

Reference

Female

32

(37.64%)

9

(28.12%)

23

(71.87%)

0.64 (0.249 to 1.669)

0.366

Technique

3DCRT

65

(76.47%)

21

(32.30%)

44

(67.69%)

Reference

IMRT

20

(23.52%)

8

(40%)

12

(60%)

1.39 (0.496 to 3.931)

0.526

Site

Upper

34

(40%)

14

(41.17%)

20 (58.82%)

Reference

Middle

19

(22.35%)

7

(36.84%)

12

(63.15%)

0.83 (0.262 to 2.646)

0.757

Lower

32

(37.64%)

8

(25%)

24

(75%)

0.47 (0.166 to 1.363)

0.166

Histology

Squamous cell carcinoma

68 (80%)

25

(36.76%)

43

Reference

Adenocarcinoma

17 (20%)

4

(23.52%)

13

0.52 (0.155 to 1.800)

0.308

Imaging

CECT

43 (50.58%)

15

(34.88%)

28

Reference

PET

9

(10.58%)

4

(44.44%)

5

1.49 (0.347 to 6.409)

0.589

Others

33

(38.82%)

10

(30.30%)

23

0.81 (0.307 to 2.144)

0.673

T status

T1-2

4 (4.70%)

3

(75%)

1

(25%)

Reference

T3-4

51(60%)

18

(35.29%)

33

(64.70%)

0.18 (0.017 to 1.878)

0.152

Unknown

30 (35.29%)

8

(26.66%)

22

(73.33%)

0.12 (0.011 to 1.340)

0.085

N status

N0

24 (28.23%)

7

(29.16%)

17

(70.83%)

Reference

N+

29

(34.11%)

11

(37.93%)

18

(62.06%)

1.48 (0.466 to 4.717)

0.503

Unknown

32

(37.64%)

11

(34.37%)

21

(65.65%)

1.27 (0.405 to 3.990)

0.679

Chemotherapy

NACT

12 (14.11%)

3

(25%)

9

(75%)

Reference

Con. Cisplatin

33

(38.82%)

11

(33.33%)

22

(66.66%)

1.50 (0.336 to 6.680)

0.594

Con Cisplatin & Taxane

19

(22.35%)

5

(26.31%)

14

(73.68%)

1.07 (0.204 to 5.625)

0.935

Radiation Dose

50.4Gy

20 (23.52%)

5 (25%)

15 (75%)

Reference

> 50.4Gy

65

(76.47%)

24

(36.92%)

41

(63.07%)

1.75 (0.567 to 5.439)

0.329